Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602335 · ClinicalTrials.gov registry record · Early Phase 1
Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT07602335: Clinical Trial Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT07602335 is a Early Phase 1 study that has not yet begun recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07602335, a Early Phase 1 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differences between the two groups. Participants will be screened for up to 28 days before starting study treatment. Following the screening visit, participants will be admitted to a clinic for 4 days for treatment with either the study drug or placebo. They will attend a follow-up visit on Days 5 and 7 and participate in a follow-up phone call on Day 8. Three different doses will be tested to find the highest safe dose.
Primary Outcome
Maximum plasma concentration in the blood after administration
Interventions
- OTHER Placebo
- DRUG MCAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-08-08 |
| Est. Completion | 2027-12-31 |
| Phase | Early Phase 1 |
What is known before NCT07602335 opens enrollment
NCT07602335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07602335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07602335 about?
NCT07602335 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants". The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differen...
What is the current status of trial NCT07602335?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2026-08-08. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07602335?
The interventions under investigation include: Placebo (OTHER), MCAM (DRUG).
Who is sponsoring clinical trial NCT07602335?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07602335's enrollment target sits among peer trials
24 1037th of 2000 higher than 913 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI